CHDI Extends Evotec Huntington's Collaboration Through 2017 | GenomeWeb

NEW YORK (GenomeWeb News) – Evotec said today that the CHDI Foundation has extended and expanded the two parties' collaboration on Huntington's disease research through 2017.

Under the terms of the agreement, CHDI will fund up to 52 full-time scientists at Evotec over the next three years. The collaboration, which began in 2006, aims to use Evotec's high-throughput screening and proteomics platforms for Huntington's drug discovery.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.